Quizartinib

Summary

Quizartinib (CHEMBL576982) is an approved small-molecule EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor (ATC L01EX11) targeting PDGFRA, PDGFRB, and KIT; indicated across 4 conditions including acute myeloid leukemia and neoplasm; with CIViC clinical evidence for 21 variant-indication associations (e.g. FLT3 D835 & I836 in acute myeloid leukemia).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EX11
• Targets: 6 (PDGFRA, PDGFRB, KIT…)
• Indications: 4 conditions
• Clinical trials: 42
• Precision-oncology evidence (CIViC): 21 variant–indication associations
• Chemistry: 560.7 Da · C29H32N6O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL576982
Name	Quizartinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	24889392
ChEBI	CHEBI:90217
ATC	L01EX11
Molecular formula	C29H32N6O4S
Molecular weight	560.7
InChIKey	CVWXJKQAOSCOAB-UHFFFAOYSA-N

SMILES: CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3

IUPAC name: 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea

ChEBI definition: A member of the class of phenylureas that is urea in which one of the amino groups has been substituted by a 5-tert-butyl-1,2-oxazol-3-yl group while the other has been substituted by a phenyl group substituted at the para- position by an imidazo[2,1-b][1,3]benzothiazol-2-yl group that, in turn, is substituted at position 7 by a 2-(morpholin-4-yl)ethoxy group.

Pharmacological roles (ChEBI): EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, antineoplastic agent, necroptosis inhibitor.

Also known as: AC-010220, Ac-220, AC-220, AC010220, AC220, ASP-2689, Quizartinib, QUIZARTINIB, AC010220.2HCL, AC 220, AC220 (QUIZARTINIB), QUIZARTINIB DIHYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL2105709

Patent coverage: 1,995 distinct patent families (4,432 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,150 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PDGFRA	platelet derived growth factor receptor alpha	Inhibition	7.96	6.2%	P16234
PDGFRB	platelet derived growth factor receptor beta	Inhibition	8.11	2.3%	P09619
KIT	KIT proto-oncogene, receptor tyrosine kinase	Inhibition	8.32	0.5%	P10721
CSF1R	colony stimulating factor 1 receptor	Inhibition	7.92	0%	P07333
FLT3	fms related receptor tyrosine kinase 3	Inhibition	8.38	0.9%	P36888
RET	ret proto-oncogene	Inhibition	8	0.4%	P07949

Broader ChEMBL bioactivity targets: 74 (assay-derived). Sample: Homeodomain-interacting protein kinase 4, Receptor-interacting serine/threonine-protein kinase 3, Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 1, Platelet-derived growth factor receptor beta, Mast/stem cell growth factor receptor Kit, Vascular endothelial growth factor receptor 3, Receptor-type tyrosine-protein kinase FLT3, Platelet-derived growth factor receptor alpha.

Bioactivity

ChEMBL activities: 353 potent at pChembl ≥ 5 of 377 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FLT3	9.7	IC50	0.2	nM	CHEMBL_ACT_25754091
FLT3	9.63	IC50	0.24	nM	CHEMBL_ACT_28884431
FLT3	9.63	IC50	0.24	nM	CHEMBL_ACT_28884899
FLT3	9.4	IC50	0.4	nM	CHEMBL_ACT_25754088
FLT3	9.25	IC50	0.56	nM	CHEMBL_ACT_29231733
FLT3	9.24	Kd	0.57	nM	CHEMBL_ACT_28884635
FLT3	9.21	IC50	0.62	nM	CHEMBL_ACT_25754096
CDK7	9.21	IC50	0.62	nM	CHEMBL_ACT_28884419
CDK7	9.21	IC50	0.62	nM	CHEMBL_ACT_28884893
CDK7	9.21	IC50	0.62	nM	CHEMBL_ACT_28884917
FLT3	9.17	IC50	0.67	nM	CHEMBL_ACT_25754099
FLT3	9.14	IC50	0.73	nM	CHEMBL_ACT_25754090
FLT3	9.1	IC50	0.8	nM	CHEMBL_ACT_3450432
FLT3	9.07	EC50	0.86	nM	CHEMBL_ACT_25754102
FLT3	9.05	IC50	0.9	nM	CHEMBL_ACT_24909848
FLT3	9.05	IC50	0.89	nM	CHEMBL_ACT_25754089
FLT3	8.96	IC50	1.1	nM	CHEMBL_ACT_18893333
FLT3	8.96	IC50	1.1	nM	CHEMBL_ACT_22960942
FLT3	8.96	IC50	1.1	nM	CHEMBL_ACT_24797158
FLT3	8.96	IC50	1.1	nM	CHEMBL_ACT_24992734
FLT3	8.96	IC50	1.1	nM	CHEMBL_ACT_26122112
FLT3	8.96	IC50	1.1	nM	CHEMBL_ACT_29231737
FLT3	8.96	IC50	1.1	nM	CHEMBL_ACT_3444908
FLT3	8.89	Kd	1.3	nM	CHEMBL_ACT_19250427
FLT3	8.89	Kd	1.3	nM	CHEMBL_ACT_19469397
FLT3	8.89	Kd	1.3	nM	CHEMBL_ACT_20679564
FLT3	8.89	Kd	1.3	nM	CHEMBL_ACT_7585814
FLT3	8.85	Kd	1.4	nM	CHEMBL_ACT_28884530
FLT3	8.82	Kd	1.5	nM	CHEMBL_ACT_28884650
FLT3	8.8	Kd	1.6	nM	CHEMBL_ACT_25755744

Target pathways

Aggregated over 6 target gene(s): PDGFRA, PDGFRB, KIT, CSF1R, FLT3, RET.

Top Reactome pathways

78 total, by targets touching each:

Pathway	Targets	Genes
RAF/MAP kinase cascade	5	FLT3, KIT, PDGFRA, PDGFRB, RET
PIP3 activates AKT signaling	4	FLT3, KIT, PDGFRA, PDGFRB
Constitutive Signaling by Aberrant PI3K in Cancer	4	FLT3, KIT, PDGFRA, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	4	FLT3, KIT, PDGFRA, PDGFRB
Downstream signal transduction	2	PDGFRA, PDGFRB
Signaling by PDGF	2	PDGFRA, PDGFRB
PI3K Cascade	1	FLT3
Developmental Biology	1	KIT
Signaling by SCF-KIT	1	KIT
Regulation of KIT signaling	1	KIT
Signal Transduction	1	KIT
Disease	1	KIT
Negative regulation of the PI3K/AKT network	1	KIT
Generic Transcription Pathway	1	KIT
PI3K/AKT Signaling in Cancer	1	KIT
Other interleukin signaling	1	CSF1R
Diseases of signal transduction by growth factor receptors and second messengers	1	KIT
MAPK family signaling cascades	1	KIT
MAPK1/MAPK3 signaling	1	KIT
RNA Polymerase II Transcription	1	KIT
Gene expression (Transcription)	1	KIT
RET signaling	1	RET
Transcriptional Regulation by VENTX	1	CSF1R
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	1	KIT
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	KIT
Intracellular signaling by second messengers	1	KIT
Signaling by Receptor Tyrosine Kinases	1	KIT
FLT3 Signaling	1	FLT3
STAT5 Activation	1	FLT3
Dasatinib-resistant KIT mutants	1	KIT

Dominant GO biological processes

GO term	Targets
cell surface receptor protein tyrosine kinase signaling pathway	6
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	6
protein phosphorylation	6
positive regulation of cell population proliferation	5
cell migration	5
positive regulation of cell migration	5
protein autophosphorylation	5
peptidyl-tyrosine phosphorylation	4
signal transduction	4
regulation of actin cytoskeleton organization	3
cell chemotaxis	3
positive regulation of ERK1 and ERK2 cascade	3
chemotaxis	3
cytokine-mediated signaling pathway	3
hemopoiesis	3

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
neoplasm	3	MONDO:0005070	EFO:0000616
liver disorder	1	MONDO:0005154	EFO:0001421
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE1	17
PHASE1/PHASE2	10
PHASE2	7
PHASE3	5
Not specified	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06578247	PHASE3	RECRUITING	Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT07478991	PHASE3	NOT_YET_RECRUITING	Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
NCT02039726	PHASE3	COMPLETED	(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
NCT02668653	PHASE3	COMPLETED	Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
NCT04676243	PHASE3	WITHDRAWN	Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician’s Choice in Newly Diagnosed FLT3-ITD+ AML
NCT03661307	PHASE1/PHASE2	RECRUITING	Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
NCT03793478	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
NCT04047641	PHASE1/PHASE2	RECRUITING	Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT04128748	PHASE1/PHASE2	RECRUITING	Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
NCT04493138	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
NCT06262438	PHASE2	RECRUITING	CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT00989261	PHASE2	COMPLETED	Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
NCT01236144	PHASE1/PHASE2	COMPLETED	A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
NCT01565668	PHASE2	COMPLETED	Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01892371	PHASE1/PHASE2	COMPLETED	Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02984995	PHASE2	COMPLETED	Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
NCT03135054	PHASE2	UNKNOWN	Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
NCT03735875	PHASE1/PHASE2	TERMINATED	Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
NCT04107727	PHASE2	COMPLETED	Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
NCT04112589	PHASE1/PHASE2	UNKNOWN	A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
NCT04209725	PHASE2	TERMINATED	A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
NCT04687761	PHASE1/PHASE2	COMPLETED	Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
NCT05735184	PHASE1	RECRUITING	A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT06740799	PHASE1	RECRUITING	Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
NCT06769490	PHASE1	RECRUITING	Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
NCT00462761	PHASE1	COMPLETED	A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT01049893	PHASE1	COMPLETED	Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
NCT01390337	PHASE1	COMPLETED	A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT01411267	PHASE1	COMPLETED	AC220 for Children With Relapsed/Refractory ALL or AML
NCT01468467	PHASE1	COMPLETED	A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
NCT02675478	PHASE1	COMPLETED	Phase 1 Study of Quizartinib
NCT02834390	PHASE1	COMPLETED	Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT03552029	PHASE1	TERMINATED	Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
NCT03723681	PHASE1	COMPLETED	Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT04459598	PHASE1	COMPLETED	A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
NCT04473664	PHASE1	COMPLETED	A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
NCT04796831	PHASE1	COMPLETED	A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects
NCT06740825	PHASE1	COMPLETED	Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects
NCT06772246	PHASE1	COMPLETED	A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate
NCT04459585	EARLY_PHASE1	COMPLETED	A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

Clinical evidence (CIViC)

Variant × indication × effect (21 predictive associations from 22 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
FLT3 D835 & I836	Acute Myeloid Leukemia	Sensitivity/Response	Lestaurtinib + Quizartinib + Sorafenib + FLT3/ABL/Aurora Kinase Inhibitor KW-2449	CIViC B	EID8925
FLT3 F691L	Acute Myeloid Leukemia	Resistance	Quizartinib	CIViC B	EID9718 +1
FLT3 D835	Acute Myeloid Leukemia	Resistance	Quizartinib + Sorafenib	CIViC B	EID1038
FLT3 N676K	Core Binding Factor Acute Myeloid Leukemia		Quizartinib + Midostaurin	CIViC B	EID8263
FLT3 D593del	Cancer	Sensitivity/Response	Sorafenib + Sunitinib + Quizartinib + Linifanib	CIViC D	EID11094
FLT3 D835V	Acute Myeloid Leukemia	Sensitivity/Response	Quizartinib	CIViC D	EID3012
FLT3 D835Y	Cancer	Sensitivity/Response	Quizartinib + KW2449 + R406 + Ponatinib + AG1295 + Sorafenib + Sunitinib + AGS324 + Linifanib	CIViC D	EID11086
FLT3 E573del	Acute Myeloid Leukemia	Sensitivity/Response	Lestaurtinib + Midostaurin + Quizartinib + Ponatinib + Sorafenib + Crenolanib	CIViC D	EID9307
FLT3 ITD	Cancer	Sensitivity/Response	FLT3 Tyrosine Kinase Inhibitor TTT-3002 + R406 + Ponatinib + Crenolanib + KW2449 + Sorafenib + Sunitinib + Quizartinib + Linifanib + AGS324 + AG1295 + Lestaurtinib + Midostaurin	CIViC D	EID11084
FLT3 ITD & D839G	Acute Myeloid Leukemia	Sensitivity/Response	Quizartinib	CIViC D	EID8896
FLT3 N841I	Acute Myeloid Leukemia	Sensitivity/Response	Quizartinib	CIViC D	EID12511
FLT3 Overexpression AND FLT3LG Expression	Cancer	Sensitivity/Response	Quizartinib + Linifanib + Lestaurtinib + Midostaurin + Ponatinib + FLT3 Tyrosine Kinase Inhibitor TTT-3002 + Sunitinib	CIViC D	EID11088
FLT3 S574del	Acute Myeloid Leukemia	Sensitivity/Response	Lestaurtinib + Crenolanib + Sorafenib + Ponatinib + Quizartinib + Midostaurin	CIViC D	EID9308
FLT3 Y572C	Acute Myeloid Leukemia	Sensitivity/Response	Quizartinib	CIViC D	EID12789
FLT3 Y572del	Acute Myeloid Leukemia	Sensitivity/Response	Quizartinib	CIViC D	EID12860
FLT3 Y572del	Acute Myeloid Leukemia	Sensitivity/Response	Midostaurin + Quizartinib + Lestaurtinib + Sorafenib + Crenolanib + Ponatinib	CIViC D	EID9306
FGF2 EXPRESSION	Acute Myeloid Leukemia	Resistance	Quizartinib	CIViC D	EID1711
FLT3 D835	Acute Myeloid Leukemia	Resistance	Ponatinib + Quizartinib	CIViC D	EID1036
FLT3 ITD AND ( FLT3 Y842C OR FLT3 Y842H )	Cancer	Resistance	Quizartinib	CIViC D	EID12628
FLT3 ITD&F691(I/L)	Acute Myeloid Leukemia	Resistance	Quizartinib	CIViC D	EID9779
FLT3 Y842C	Acute Myeloid Leukemia	Resistance	Quizartinib	CIViC D	EID8654

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

188 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
Crizotinib	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
AXITINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
BOSUTINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
DASATINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
FEDRATINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
NILOTINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
NINTEDANIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
PONATINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
SORAFENIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
SUNITINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
VANDETANIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
CEDIRANIB	ChEMBL	Phase 3	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
DOVITINIB	ChEMBL	Phase 3	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
LESTAURTINIB	ChEMBL	Phase 3	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
LINIFANIB	ChEMBL	Phase 3	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
MOTESANIB	ChEMBL	Phase 3	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
SEMAXANIB	ChEMBL	Phase 3	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
CENISERTIB	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
DEFOSBARASERTIB	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
DORAMAPIMOD	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
FORETINIB	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
ILORASERTIB	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
R-406	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
RAF-265	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
SU-014813	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
TOZASERTIB	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
Idelalisib	PubChem	Approved	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
Selumetinib	PubChem	Approved	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET
Gefitinib	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, RET
IMATINIB	ChEMBL + PubChem	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB
ERLOTINIB	ChEMBL	Phase 4 (approved)	FLT3, KIT, PDGFRA, PDGFRB, RET
PEXIDARTINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, PDGFRA, PDGFRB
TIVOZANIB	ChEMBL	Phase 4 (approved)	FLT3, KIT, PDGFRA, PDGFRB, RET
BARASERTIB	ChEMBL	Phase 3	FLT3, KIT, PDGFRA, PDGFRB, RET
BRIVANIB	ChEMBL	Phase 3	CSF1R, KIT, PDGFRA, PDGFRB, RET
CANERTINIB	ChEMBL	Phase 3	FLT3, KIT, PDGFRA, PDGFRB, RET
SARACATINIB	ChEMBL	Phase 3	FLT3, KIT, PDGFRA, PDGFRB, RET
VATALANIB	ChEMBL	Phase 3	CSF1R, KIT, PDGFRA, PDGFRB, RET
VIMSELTINIB	ChEMBL	Phase 3	CSF1R, FLT3, KIT, PDGFRA, PDGFRB
CEP-32496	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRB, RET
ENMD-2076	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, RET
REBASTINIB	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, RET
SOTULETINIB	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB
TANDUTINIB	ChEMBL	Phase 2	CSF1R, FLT3, KIT, PDGFRA, PDGFRB
BRIGATINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, RET
CERITINIB	ChEMBL	Phase 4 (approved)	FLT3, KIT, PDGFRA, RET
ENTRECTINIB	ChEMBL	Phase 4 (approved)	CSF1R, FLT3, KIT, RET
INFIGRATINIB	ChEMBL	Phase 4 (approved)	FLT3, KIT, PDGFRA, RET
LENVATINIB	ChEMBL	Phase 4 (approved)	KIT, PDGFRA, PDGFRB, RET
ALVOCIDIB	ChEMBL	Phase 3	CSF1R, FLT3, KIT, PDGFRA
CRENOLANIB	ChEMBL	Phase 3	FLT3, PDGFRA, PDGFRB, RET
MASITINIB	ChEMBL	Phase 3	CSF1R, KIT, PDGFRA, PDGFRB
BEMCENTINIB	ChEMBL	Phase 2	FLT3, KIT, PDGFRA, RET
BMS-777607	ChEMBL	Phase 2	FLT3, KIT, PDGFRA, RET
CEP-11981	ChEMBL	Phase 2	CSF1R, FLT3, PDGFRA, RET
MILCICLIB	ChEMBL	Phase 2	FLT3, KIT, PDGFRB, RET